QSI GC & Corp. Secretary Christian Lapointe Sells $14K of Stock

Christian Lapointe Executes QSI Stock Sale

Christian Lapointe, who serves as General Counsel and Corporate Secretary for Quantum-Si, executed a sale of 15,588 shares on June 22, 2026. The transaction took place at a price of $0.93 per share, resulting in a total value of roughly $14,496.84. This move forms part of a broader wave of executive stock sales at the life sciences firm during late June, highlighting active portfolio adjustments among top leaders.

A Broader Trend of Executive Transactions

The June disposition by Lapointe was accompanied by several other leadership filings at Quantum-Si. President and CEO Jeffrey Alan Hawkins parted with 11,310 shares on June 22, 2026, at a price of $0.96 for a total value of $10,857.60, followed by an additional sale of 11,311 shares on June 23, 2026, at $0.90 per share worth $10,179.90. Chief Financial Officer Jeffry Keyes also trimmed his stake, selling 4,116 shares at $0.96 on June 22, 2026, for $3,951.36 and another 4,117 shares at $0.90 on June 23, 2026, valued at $3,705.30. Chief Product Officer John Vieceli joined the group on June 23, 2026, by selling 15,112 shares at $0.90 for a total of $13,600.80, while Christian Lapointe executed a follow-up sale of 7,794 shares on June 23, 2026, at $0.90 per share totaling $7,014.60.

QSI Trading Levels and Market Position

Shares of QSI changed hands around $0.83 recently, sitting above their 52-week low of $0.69 while remaining well below the 52-week high of $3.10. The medical device maker carries a market capitalization of approximately $165.48 million. The stock changes hands near its 50-day moving average of $0.78, while staying under its 200-day moving average of $0.97. Because the firm is not currently profitable, it does not carry a meaningful forward earnings multiple.

Recent Financial Results

Quantum-Si reported revenue of $1.61 million for the period, accompanied by a revenue growth rate of -41.8%. The enterprise posted basic earnings per share of -0.46, alongside a net margin of 0.0 and a return on equity of -49.11%. Investors continue to monitor cash management and product adoption across the company's single-molecule detection platform.

Analysts Set New Price Targets

Wall Street firms maintain active coverage on the medical device maker, led by HC Wainwright & Co., which reiterated its buy rating on the stock with a $4.00 price target on September 29, 2026. Across the broader analytical community, QSI holds a consensus mean target price of $2.30 based on three analyst opinions, with targets spanning from a low of $1.00 to a high of $4.00.

Inside Quantum-Si's Business Operations

Headquartered in Branford, Connecticut, Quantum-Si operates as a life sciences company focused on developing proprietary, universal single-molecule detection platforms applied to proteomics. The business enables next-generation protein sequencing through platforms like Platinum and Platinum Pro, alongside specialized library preparation kits and cloud-based analysis software designed to automate data workflows.

What to Watch Next for QSI

Market participants are tracking the company's operational milestones and upcoming disclosures, with the next financial update scheduled for November 5, 2026. Insider transactions remain individual choices reflecting personal financial management rather than formal operational signals, and stakeholders will look to upcoming regulatory filings for further clarity on insider ownership trends.